Bristol Myers Squibb Receives Positive CHMP Opinion Recommending Approval for LAG-3-Blocking Antibody Combination Opdualag (nivolumab and relatlimab) for Treatment of Patients with Unresectable or Metastatic MelanomaBusiness Wire • 07/22/22
Earnings Preview: Bristol Myers Squibb (BMY) Q2 Earnings Expected to DeclineZacks Investment Research • 07/20/22
Bristol Myers Squibb Launches Disability Diversity in Clinical Trials (DDiCT) Initiative to Improve Healthcare Outcomes for People with DisabilitiesBusiness Wire • 07/20/22
TURNING POINT THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Turning Point Therapeutics, Inc. - TPTXBusiness Wire • 07/05/22
Bristol-Myers Squibb: Annual Mid Single-Digit Growth Equals Incremental UpsideSeeking Alpha • 06/28/22